North American Scientific Regains Compliance on Nasdaq Capital Markets
May 21 2008 - 8:27PM
Business Wire
North American Scientific, Inc. (the �Company�) (Nasdaq: NASM)
today announced that it received a letter from The Nasdaq Stock
Market (�Nasdaq�) dated May 15, 2008 providing notice that their
bid price deficiency has been cured. As a result of regaining
compliance with Nasdaq Marketplace Rules, The Nasdaq Listing
Qualifications Panel has determined that the hearing scheduled for
May 22, 2008 is no longer necessary. The Company�s common stock
will continue to be listed on The Nasdaq Capital Market and will
continue to trade under the symbol �NASM.� About North American
Scientific North American Scientific is a leader in radiation
therapy in the fight against cancer. Its innovative products
provide physicians with tools for the treatment of various types of
cancers. They include Prospera� brachytherapy seeds and SurTRAK�
needles and strands used primarily in the treatment of prostate
cancer. In addition, the Company has been gaining clinical
experience with its first generation ClearPath� multi-channel
catheter breast brachytherapy devices in 2007, and intends to
launch the second generation devices in 2008. They are the only
such devices approved for both high dose and continuous release, or
low dose, radiation treatments. The devices are designed to provide
flexible, precise dose conformance and an innovative delivery
system that is intended to offer the more advanced form of
brachytherapy for the treatment of breast cancer. Please visit
www.nasmedical.com for more information. Statements included in
this release that are not historical facts may be considered
forward-looking statements that are subject to a variety of risks
and uncertainties. There are a number of important factors that
could cause actual results to differ materially from those
expressed in any forward-looking statements made by the Company
including, but not limited to, the impact of competitive products
and pricing, technological changes, changes in relationships with
strategic partners and dependence upon strategic partners for the
performance of critical activities under collaborative agreements,
the ability of the Company to successfully directly market and sell
its products, uncertainties relating to patent protection and
regulatory approval, the stable supply of appropriate isotopes,
research and development estimates, market opportunities, risks
associated with strategic opportunities or acquisitions the Company
may pursue and the risk factors included in the Company�s filings
with the Securities and Exchange Commission. Any forward-looking
statements contained in this news release speak only as of the date
of this release, and the Company undertakes no obligation to revise
or update any forward-looking statements, whether as a result of
new information, future results or otherwise.
North American Scientific (MM) (NASDAQ:NASM)
Historical Stock Chart
From Sep 2024 to Oct 2024
North American Scientific (MM) (NASDAQ:NASM)
Historical Stock Chart
From Oct 2023 to Oct 2024